NASDAQ$AKYA

Akoya Biosciences Inc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Akoya reported a record quarterly revenue and grew its installed base.

Akoya Biosciences reported a strong finish to 2021 with record quarterly revenue of $16.2 million, representing a 26% increase compared to the prior year period. The company's installed base grew to nearly 700 instruments worldwide, and there are approximately 500 publications on Akoya platforms to date. The commercial launch of the PhenoCycler™-Fusion System was a highlight of the quarter.

  • Total revenue was $16.2 million, a 26% increase compared to the prior year period.
  • Product revenue was $12.9 million, a 23% increase compared to the prior year period.
  • Services and other revenue totaled $3.2 million, a 33% increase compared to the prior year period.
  • Gross profit was $10.2 million, a 29% increase compared to the prior year period, with a gross profit margin of 63.3%.

Headline financials

Total Revenue

$16.2M

Previous: $12.9M+25.2%
EPS (adj)

-$0.47

Previous: $2.49-118.9%
Capital Expenditures

$1.37M

Previous: $487K+180.3%
Free Cash Flow

-$7.22M

Previous: -$2.63M-174.1%
Net Income

-$17.7M

Previous: -$5.69M-210.4%
Operating Income

-$16.8M

Previous: -$3.15M-432.9%
Gross Profit

$10.2M

Previous: $7.91M+29.3%
Cash & Equivalents

$113M

Previous: $17M+564.9%
Total Assets

$191M

Previous: $77.7M+145.8%
Stock-Based Comp

$1.41M

Previous: $54K+2513.0%

Revenue & EPS history

Akoya · Revenue · Quarterly

$16.2M

Q4 2021+25.2%vs Q4 2020
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Akoya · $16.2M total across 2 segments · Q4 2021

  • Product revenue
    $12.9M+23.4%
  • Service and other revenue
    $3.24M+32.8%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports

Historical avg

-3.7%

Avg return

Earnings day

-8.6%

Avg return

5 days after

-17.2%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+13.7%

Q4 2021

Best reaction

-31.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025
Q1 2025+1.0%+24.8%+23.8%
Q4 2025+3.8%+9.2%-30.7%
Q3 2024-24.9%-33.2%-29.5%
Q2 2024-9.5%-0.9%+5.5%
Q1 2024-31.9%-35.1%-50.0%
Q4 2023-15.4%-17.1%-28.1%
Q3 2023+10.0%+6.9%+16.4%
Q2 2023+0.9%-6.5%-23.9%
Q1 2023-2.5%-17.1%-18.8%
Q4 2022-7.3%-17.2%-36.6%
Q3 2022-15.1%
Q2 2022+5.0%
Q1 2022-11.9%
Q4 2021+13.7%
Q3 2020+1.5%
Q3 2021+0.2%
Q2 2021-0.1%
Q4 2020+9.5%
Q1 2021+2.3%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro